AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AgomAb Therapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026
$8.23−0.05 (-0.60%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
80.6%
28M of 34M shares
Institutional holders
34
9 new, 7 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 5,141,992 | 10.60% | 13D (active) | Feb 9, 2026 |
| Abigail P. Johnson | 4,873,680 | 10.00% | 13G (passive) | Feb 27, 2026 |
| Tomer Kariv | 3,305,846 | 6.80% | 13G (passive) | Mar 31, 2026 |
| Sanofi | 2,783,096 | 5.71% | 13G (passive) | Mar 31, 2026 |
| Redmile Group, LLC | 2,735,926 | 5.60% | 13G (passive) | Mar 31, 2026 |
| Bihua Chen | 2,465,348 | 5.01% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AGMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | 15.05% | $66.74M | – | 7.74% |
| Nantahala Capital Management, LLC | 3,136,376 | 9.18% | $40.71M | +1,936,376 | 0.68% |
| Sanofi | 2,783,096 | 8.15% | $36.12M | – | 6.76% |
| Redmile Group, LLC | 2,733,926 | 8.00% | $35.49M | +2,577,676 | 2.38% |
| Cormorant Asset Management, LP | 2,465,348 | 7.22% | $32.00M | – | 1.64% |
| TCG Crossover Management, LLC | 2,053,233 | 6.01% | $26.65M | – | 0.64% |
| Federated Hermes, Inc. | 1,618,000 | 4.74% | $21.00M | – | 0.03% |
| Casdin Capital, LLC | 1,550,000 | 4.54% | $20.12M | – | 1.01% |
| Andera Partners | 1,538,702 | 4.50% | $19.97M | – | 9.67% |
| FMR LLC | 1,458,677 | 4.27% | $18.93M | – | 0.00% |
| abrdn plc | 846,695 | 2.48% | $10.99M | +139,039 | 0.02% |
| Perceptive Advisors LLC | 600,000 | 1.76% | $7.79M | – | 0.12% |
| Samsara BioCapital, LLC | 600,000 | 1.76% | $7.79M | – | 0.64% |
| Siren, L.L.C. | 411,250 | 1.20% | $5.34M | – | 0.11% |
| Orbimed Advisors LLC | 192,740 | 0.56% | $2.50M | New | 0.05% |
| Pfizer Inc | 75,000 | 0.22% | $1.04M | – | 0.61% |
| Alps Advisors Inc | 49,984 | 0.15% | $648.79K | New | 0.00% |
| Bellevue Group AG | 49,248 | 0.14% | $639.24K | −752 | 0.01% |
| Seven Grand Managers, LLC | 47,600 | 0.14% | $617.85K | −152,400 | 0.02% |
| Sectoral Asset Management Inc | 43,500 | 0.13% | $564.63K | – | 0.39% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 34 | 28M | 80.6% | 9 / 4 | 6 / 7 | 5M | 1M |
| Q1 2026 | 32 | 23M | 68.4% | 32 / 0 | 0 / 0 | 23M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AGMB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 981,184 | 2.87% | $12.63M | 0.26% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 615,708 | 1.80% | $7.92M | 0.28% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 507,877 | 1.49% | $5.71M | 0.01% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 141,356 | 0.41% | $1.59M | 0.01% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 129,200 | 0.38% | $1.45M | 0.01% | May 31, 2026 |
| Federated Hermes Kaufmann Fund II | 21,108 | 0.06% | $273.98K | 0.24% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 17,665 | 0.05% | $229.29K | 0.01% | Jun 30, 2026 |
| Select Pharmaceuticals Portfolio | 9,100 | 0.03% | $102.38K | 0.01% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 8,746 | 0.03% | $98.39K | 0.00% | May 31, 2026 |
| Steward Values Enhanced International Fund | 4,109 | 0.01% | $52.88K | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Tim Jasper Knotnerus | Chief Executive Officer, Director | 45,217 | 0.13% | Mar 18, 2026 |
| der Horst Paul Henryk van | Chief Business Officer | – | – | Mar 18, 2026 |
| Ellen Lefever | General Counsel | – | – | Mar 18, 2026 |
| Andrea Saez Borderias | Chief Development Officer | – | – | Mar 18, 2026 |
| Philippe Constantin Wiesel | Chief Medical Officer | – | – | Mar 18, 2026 |
| Pierre Thadee Victor Kemula | Chief Financial Officer | – | – | Mar 18, 2026 |
| Marino Garcia | Director | – | – | Sep 15, 2026 |
| Naimish Patel | Director | – | – | Sep 15, 2026 |
| Weegen Felice Isabel Verduyn-van | Director | – | – | Mar 18, 2026 |
| Angelika Martha Jahreis | Director | – | – | Mar 18, 2026 |
| Colin Michael Bond | Director | – | – | Mar 18, 2026 |
| David R. Epstein | Director | – | – | Mar 18, 2026 |
| Ohad Hammer | Director | – | – | Mar 18, 2026 |